RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease

Current Hypertension Reports

Volumn 5, Issue 5, 2003, Pages 408-417

  Lakkis, Jay ^b   Lu, Wei X ^b   Weir, Matthew R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; CAPTOPRIL; CORTICOTROPIN; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; LOOP DIURETIC AGENT; LOSARTAN; SPIRONOLACTONE; TRANDOLAPRIL; VASODILATOR AGENT; DRUG DERIVATIVE;

ARTERY COMPLIANCE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLLAGEN SYNTHESIS; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; ESSENTIAL HYPERTENSION; GENETIC POLYMORPHISM; GYNECOMASTIA; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART VENTRICLE REMODELING; HUMAN; HYPERKALEMIA; IMPOTENCE; KIDNEY DISEASE; LIBIDO DISORDER; MASTALGIA; MENSTRUAL IRREGULARITY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIMARY HYPERALDOSTERONISM; PROTEIN URINE LEVEL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; URINARY EXCRETION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; DRUG ANTAGONISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALDOSTERONE; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY DISEASES; RECEPTORS, ALDOSTERONE; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE;

EID: 0642373665     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-003-0087-9     Document Type: Review

References (95)

1. Basso N, Terragno NA: History about the discovery of the renin-angiotensin system. Hypertension 2001, 38:1246-1249.
2. Rohrwasser A, Morgan T, Dillon HF: Elements of a paracrine tubular renin-angiotensin system along the entire nephron. Hypertension 1999, 34:1265-1274.
3. Bader M: Role of the local renin-angiotensin system in cardiac damage: a minireview focussing on transgenic animal models. J Mol Cell Cardiol 2002, 34:1455-1462.
4. Bader M, Ganten D: It's renin in the brain: transgenic animals elucidate the brain renin angiotensin ystem. Circ Res 2002, 90:8-10.
5. Ganten D, Hermann K, Bayer C, et al.: Angiotensin synthesis in the brain and increased turnover in hypertensive rats. Science 1983, 221:869-871.
6. Senanayake PD, Moriguchi A, Kumagai H, et al.: Increased expression of angiotensin peptides in the brain of transgenic hypertensive rats. Peptides 1994, 15:919-926.
7. Shibata K, Komatsu C, Misumi Y, Furukawa T: Developmental differences of angiotensinogen mRNA in the preoptic area between spontaneously hypertensive and age-matched Wistar-Kyoto rats. Brain Res Mol Brain Res 1993, 19:115-120.
8. Wright JW, Harding JW: Regulatory role of brain angiotensins in the control of physiological and behavioral responses. Brain Res Brain Res Rev 1992, 17:227-262.
9. Unger T, Culman J, Gohlke P: Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens Suppl 1998, 16:S3-S9.
10. Grekin RJ, Terris JM, Bohr DF: Electrolyte and hormonal effects of deoxycorticosterone acetate in young pigs. Hypertension 1980, 2:326-332.
11. Grekin RJ, Sider RS: Aldosterone receptor measurements during changes in dietary sodium. Endocrinology 1981, 108:109-112.
12. Lehoux JG, Bellabarba D, Beaudry C: Corticosteroid receptors in the kidney of chick embryo. III. Nature, properties, and ontogeny of aldosterone receptor. Gen Comp Endocrinol 1984, 53:116-125.
13. Golestaneh N, Picaud S, Mirshahi M: The mineralocorticoid receptor in rodent retina: ontogeny and molecular identity. Mol Vis 2002, 8:221-225.
14. Farman N, Kusch M, Edelman IS: Aldosterone receptor occupancy and sodium transport in the urinary bladder of Bufo marinus. Am J Physiol 1978, 235:C90-C96.
15. Herkner K, Pollak A, Swoboda W, Holler B: Explanation of the pseudohypoaldosteronism (PHA)-stress syndrome with an artificial aldosterone receptor model. J Steroid Biochem 1984, 20:317-320.
16. Hatakeyama H, Miyamori I, Fujita T: Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994, 269:24316-24320.
17. Nichols NR, Hall CE, Meyer WJ: Decreased aldosterone receptor affinity in aortic cells from the Fischer 344 rat. J Hypertens 1983, 1:393-397.
18. Anderson NS III, Fanestil DD: Corticoid receptors in rat brain: evidence for an aldosterone receptor. Endocrinology 1976, 98:676-684.
19. Moguilewsky M, Raynaud JP: Evidence for a specific mineralo-corticoid receptor in rat pituitary and brain. J Steroid Biochem 1980, 12:309-314.
20. McEwen BS, Lambdin LT, Rainbow TC, De Nicola AF: Aldosterone effects on salt appetite in adrenalectomized rats. Neuroendocrinology 1986, 43:38-43.
21. Gerlach JL, McEwen BS: Rat brain binds adrenal steroid hormone: radioautography of hippocampus with corticosterone. Science 1972, 175:1133-1136.
22. De Kloet R, Wallach G, McEwen BS: Differences in corticosterone and dexamethasone binding to rat brain and pituitary. Endocrinology 1975, 96:598-609.
23. Birmingham MK, Stumpf WE, Sar M: Nuclear localization of aldosterone in rat brain cells assessed by autoradiography. Experientia 1979, 35:1240-1241.
24. De Nicola AF, Tornello S, Weisenberg L, et al.: Uptake and binding of [3H]aldosterone by the anterior pituitary and brain regions in adrenalectomized rats. Horm Metab Res 1981, 13:103-106.
25. Schwartz B, Wysocki A: Mineralocorticoid receptors in the rabbit iris-ciliary body. Ophthalmic Res 1997, 29:42-47.
26. Pratt WB: The role of heat shock proteins in regulating the function, folding, and trafficking of the glucocorticoid receptor. J Biol Chem 1993, 268:21455-21458.
27. Fanestil DD, Kipnowski J: Molecular action of aldosterone. Klin Wochenschr 1982, 60:1180-1185.
28. Bhargava A, Fullerton MJ, Myles K, et al.: The serum- and glucocorticoid-induced kinase is a physiological mediator of aldosterone action. Endocrinology 2001, 142:1587-1594.
29. Granger JP, Kassab S, Novak J, et al.: Role of nitric oxide in modulating renal function and arterial pressure during chronic aldosterone excess. Am J Physiol 1999, 276:R197-R202.
30. Lombes M, Alfaidy N, Eugene E, et al.: Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995, 92:175-182.
31. Roland BL, Krozowski ZS, Funder JW: Glucocorticoid receptor, mineralocorticoid receptors, 11 beta-hydroxysteroid dehydrogenase-1 and -2 expression in rat brain and kidney: in situ studies. Mol Cell Endocrinol 1995, 111:R1-R7.
32. Takeda Y, Miyamori I, Inaba S, et al.: Vascular aldosterone in genetically hypertensive rats. Hypertension 1997, 29:45-48.
33. Christ M, Douwes K, Eisen C, et al.: Rapid effects of aldosterone on sodium transport in vascular smooth muscle cells. Hypertension 1995, 25:117-123.
34. Alzamora R, Michea L, Marusic ET: Role of libeta-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension 2000, 35:1099-1104.
35. Inglis JA, Halliday JW: Renal damage after subtotal nephrectomy. Pathology 1969, 1:177-183.
36. Quan ZY, Walser M, Hill GS: Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int 1992, 41:326-333.
37. Akimov I, Kosithyn NS: Influence of unilateral nephrectomy on aldosterone receptors in the remaining kidney in rats. Izv Akad Nauk Ser Biol 2002, 597-600.
38. Ullian ME, Gantt BJ, Ford AK, et al.: Potential importance of glomerular citrate synthase activity in remnant nephropathy. Kidney Int 2003, 63:156-164.
39. Ullian ME, Robinson CJ, Evans CT, et al.: Role of citrate synthase in aldosterone-mediated sodium reabsorption. Hypertension 2000, 35:875-879.
40. Fitzgibbon WR, Greene EL, Grewal JS, et al.: Resistance to remnant nephropathy in the Wistar-Furth rat. J Am Soc Nephrol 1999, 10:814-821.
41. Ullian ME, Islam MM, Robinson CJ, et al.: Resistance to mineralocorticoids in Wistar-Furth rats. Am J Physiol 1997, 272:H1454-H1461.
42. Kenyon CJ, Deconti GA, Cupolo NA, Morris DJ: The role of aldosterone in the development of hypertension in spontaneously hypertensive rats. Endocrinology 1981, 109:1841-1845.
43. Gavras H, Brunner HR, Laragh JH: Renin and aldosterone and the pathogenesis of hypertensive vascular damage. Prog Cardiovasc Dis 1974, 17:39-49.
44. Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996, 98:1063-1068.
45. Rocha R, Chander PN, Khanna K, et al.: Mineral ocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31:451-458.
46. Rocha R, Chander PN, Zuckerman A, Stier CT Jr: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999, 33:232-237.
47. Rocha R, Stier CT Jr, Kifor I, et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141:3871-3878.
48. Clore J, Schoolwerth A, Watlington CO: When is cortisol a mineralocorticoid? Kidney Int 1992, 42:1297-1308.
49. Lifton RP, Dluhy RG, Powers M, et al.: A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992, 355:262-265.
50. Hautanena A, Lankinen L, Kupari M, et al.: Associations between aldosterone synthase gene polymorphism and the adrenocortical function in males. J Intern Med 1998, 244:11-18.
51. Brand E, Schorr U, Ringel J, et al.: Aldosterone synthase gene (CYP11B2) C-344T polymorphism in Caucasians from the Berlin Salt-Sensitivity Trial (BeSST). J Hypertens 1999, 17:1563-1567.
52. Patel S, Steeds R, Channer K, Samani NJ: Analysis of promoter region polymorphism in the aldosterone synthase gene (CYP11B2) as a risk factor for myocardial infarction. Am J Hypertens 2000, 13:134-139.
53. Hengstenberg C, Holmer SR, Mayer B, et al.: Evaluation of the aldosterone synthase (CYP11B2) gene polymorphism in patients with myocardial infarction. Hypertension 2000, 35:704-709.
54. Hautanen A, Toivanen P, Mantrari M, et al.: Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction. Circulation 1999, 100:2213-2218.
55. Matsubara M, Omori F, Fujita S, et al.: Haplotypes of aldosterone synthase (CYP11B2) gene in the general population of Japan: the Ohasama study. Clin Exp Hypertens 2001, 23:603-610.
56. Matsubara M, Kikuya M, Ohkubo T, et al.: Aldosterone synthase gene (CYP11B2) C-334T polymorphism, ambulatory blood pressure and nocturnal decline in blood pressure in the general Japanese population: the Ohasama Study. J Hypertens 2001, 19:2179-2184.
57. Chen A, Zhang W, Tang X, et al.: The relationship of aldosterone synthase gene polymorphism with hypertension and left ventricular hypertrophy. Zhonghua Nei Ke Za Zhi 2002, 41:298-301.
58. Chen AH, Zhang WX, Li ZL, et al.: Association between aldosterone synthase gene polymorphism and hypertrophic cardiomyopathy. Di Yi Jun Yi Da Xue Xue Bao 2002, 22:704-706.
59. Lacolley P, Labat C, Pujol A, et al.: Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002, 106:2848-2853.
60. Neves MF, Virdis A, Schiffrin EL: Resistance artery mechanics and composition in angiotensin II-infused rats: effects of aldosterone antagonism. J Hypertens 2003, 21:189-198.
61. Ullian ME, Walsh LG, Morinelli TA: Potentiation of angiotensin II action by corticosteroids in vascular tissue. Cardiovasc Res 1996, 32:266-273.
62. Rocha R, Martin-Berger CL, Yang P, et al.: Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002, 143:4828-4836.
63. Suzuki G, Morita H, Mishima T, et al.: Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002, 106:2967-2972.
64. Romagni P, Rossi F, Guerrini L, et al.: Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 2003, 166:345-349.
65. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
66. Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
67. Ardaillou R: Angiotensin II receptors. J Am Soc Nephrol 1999, 10(11):S30-S39.
68. Sato A, Suzuki Y, Shibata H, Saruta T: Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients. Hypertens Res 2000, 23:25-31.
69. Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003, 41:64-68.
70. Sato A, SarutaT: Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001, 29:13-21.
71. Cicoira M, Zanolla L, Rossi A, et al.: Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 2001, 37:1808-1812.
72. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987, 316:1429-1435.
73. Cicoira M, Zanolla L, Franceschini L, et al.: Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2002, 89:403-407.
74. Shiigai T, Shichiri M: Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease. Am J Kidney Dis 2001, 37:477-483.
75. Li S, Wu P, Zhong S, et al.: Effects of long-term enalapril and losartan therapy of hypertension on cardiovascular aldosterone. Horm Res 2001, 55:293-297.
76. Xiu JC, Wu P, Xu JP, et al.: Effects of long-term enalapril and losartan therapy of heart failure on cardiovascular aldosterone. J Endocrinol Invest 2002, 25:463-468.
77. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
78. Wong M, Staszewsky L, Latini R, et al.: Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002, 40:970-975.
79. Agarwal R: Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001, 59:2282-2289.
80. Zannad F, Alla F, Dousset B, et al.: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102:2700-2706.
81. Kasama S, Toyama T, Kumakura H, et al.: Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 2002, 43:1279-1285.
82. Cicoira M, Zanolla L, Rossi A, et al.: Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2002, 40:304-310.
83. Tsutamoto T, Wada A, Maeda K, et al.: Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001, 37:1228-1233.
84. Pitt B, Williams G, Remme W, et al.: The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001, 15:79-87.
85. Spertus JA, Tooley J, Jones P, et al.: Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuro-Hormonal Efficacy and SUrvival Study). Am Heart J 2002, 143:636-642.
86. Epstein M, Buckalew V, Martinez F, et al.: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination in diabetic hypertensives with microalbuminuria [abstract]. Am J Hypertens 2002, 15:24A.
87. de Gasparo M, Joss U, Ramjoue HP, et al.: Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987, 240:650-656.
88. de Gasparo M, Cumin F, Nussberger J, et al.: Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers. Br J Clin Pharmacol 1989, 27:587-596.
89. Delyani JA: Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 2000, 57:1408-1411.
90. Weinberger MH, Roniker B, Krause SL, Weiss RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15:709-716.
91. Krum H, Nolly H, Workman D, et al.: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002, 40:117-123.
92. Krum H, Nolly H, Roniker B, et al.: Coadministration of eplerenone with an angiotensin-converting enzyme inhibitor or an angiotensin II blocker in patients with mild to moderate hypertension (supplement). Eur Heart J 2001, 22:612.
93. Ibrahim HN, Rosenberg ME, Hostetter TH: Role of the renin-angiotensin-aldosterone system in the progression of renal disease: a critical review. Semin Nephrol 1997, 17:431-440.
94. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 1997, 51:2-15.
95. Epstein M: Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives. Intern Med 2001, 40:573-583.